10 recruiting, 9 completed, 7 not yet recruiting, 7 unknown. 8 Phase 3, 6 Not applicable, 4 Phase 4, 3 Phase 1, 3 Phase 2.
Follow T2DM: new trials by email Literature Review of T2DM trials Research Report on T2DM
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PREDICT-DM: Community Pharmacy-Based Point-of-Care Testing for Undiagnosed T2DM Diabetes Mellitus, Type 2, Prediabetic State | Not yet recruiting | Universiti Sains Malaysia | 480 | 2026-10-01 | 2026-08-31 | |
| Endocrine Disruption, Menopause, and Poor Sleep in wOmen With Type 2 Diabetes: Effects on Cardiovascular Health 4 years of clinical evaluations. - Menopause, Sleep Disruption | Not yet recruiting | Ottawa Heart Institute Research Corporation | 381 | 2026-09-01 | 2026-07-01 | |
| Integrated Diabetes and Oral Health Care in Oman Health Belief Model-Based Integrated Diabetes-Oral Health Educational Intervention, Standard Diabetes Education and Routine Care - Type 2 Diabetes Mellitus, Periodontitis | Not applicable | Not yet recruiting | Oman Ministry of Health | 290 | 2026-09-01 | 2026-09-09 |
| A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes Mellitus HRS9531 Tablet, HRS9531 Tablet placebo - T2DM | Phase 2 | Recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 240 | 2026-07-14 | 2026-07-23 |
| A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease. HTD1801, placebo - T2DM, CKD | Phase 2 | Recruiting | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences | 75 | 2026-07-09 | 2026-07-15 |
| Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus HM15275, Placebo of HM15275 - Type 2 Diabetes Mellitus, T2DM | Phase 2 | Recruiting | Hanmi Pharmaceutical Company Limited | 180 | 2026-05-18 | 2026-10-19 |
| The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD alogliptin and actoplus met, actoplus met - T2DM, MAFLD | Phase 4 | Not yet recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 80 | 2026-05-01 | 2026-03-24 |
| A Single-Center, Open-Label, Single Ascending Dose Study of Exenatide Circular RNA-Lipid Nanoparticle Injection (CR059) in Chinese Subjects With Type 2 Diabetes Mellitus Exenatide Circular RNA-Lipid Nanoparticle Injection（ CR059）） - T2DM | Early Phase 1 | Recruiting | The First Affiliated Hospital of Henan University of Science and Technology | 9 | 2026-01-20 | 2026-04-06 |
| Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine CGM-Augmented FIM, FIM only - Nutrition, Type 2 Diabetes | Not applicable | Active not recruiting | University of North Carolina, Chapel Hill | 60 | 2025-09-19 | 2026-08-17 |
| The Effect of Semaglutide on Bone Health semaglutide combined with metformin - Osteoporosis, Osteoporosis Fracture | Phase 4 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 150 | 2025-09-15 | 2025-09-17 |
| Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D Fitbit and AI Chatbot, Routine Care - Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM) | Completed | University of Colorado, Denver | 35 | 2025-09-03 | 2026-08-19 | |
| Detecting Type 2 Diabetes From Voice Type 2 Diabetes, Diabetes (DM) | Completed | Thymia Limited | 7319 | 2025-09-01 | 2026-03-19 | |
| A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone RAY1225, placebo - T2DM | Phase 3 | Not yet recruiting | Guangdong Raynovent Biotech Co., Ltd | 350 | 2025-08-31 | 2025-08-24 |
| A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes RAY1225, Semaglutide - T2DM | Phase 3 | Not yet recruiting | Guangdong Raynovent Biotech Co., Ltd | 600 | 2025-08-31 | 2025-08-24 |
| Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes. SGLT2i+Metformin+Cofrogliptin, SGLT2i+Metformin+Linagliptin - T2DM | Phase 4 | Recruiting | Huazhong University of Science and Technology | 170 | 2025-07-30 | 2025-06-13 |
| Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin Metformin, Alogliptin, empagliflozin - T2DM, Diabete Type 2 | Phase 3 | Recruiting | Celltrion | 171 | 2025-07-18 | 2025-08-11 |
| Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes Ca-1000, Ca-500, Control - T2DM | Not applicable | Recruiting | University of Adelaide | 8 | 2025-05-22 | 2025-12-26 |
| Embecta AID System in Adults With Type 2 Diabetes An AID System., Standard of Care (SC) - Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM) | Not applicable | Withdrawn | Embecta Corp. | 2025-01-01 | 2024-12-16 | |
| Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin CT-L03 Group 1, CT-L03 Group 2, Placebo - T2DM | Phase 3 | Completed | Celltrion | 606 | 2024-08-27 | 2026-05-15 |
| Comprehensive Clinical Evaluation Study of GLP-1RA T2DM | Recruiting | LI YAN | 492 | 2024-07-01 | 2024-11-13 |
Showing 20 of 35. Sign in to see all of them.
Diabetes Mellitus, Type 2 (12) · Diabetes Mellitus (2) · Obesity (2) · Depression (1) · Diabetic Nephropathies (1) · Gingivitis (1) · Glucose Intolerance (1) · Hypertension (1) · Metabolic Syndrome (1) · Motor Activity (1) · Osteoporosis (1) · Osteoporotic Fractures (1) · Periodontal Diseases (1) · Periodontitis (1) · Prediabetic State (1)
Nutritional and Metabolic Diseases (15) · Metabolic Diseases (14) · Endocrine System Diseases (13) · Glucose Metabolism Disorders (13) · Diabetes Mellitus (11) · Behavior (2) · Body Weight (2) · Nutrition Disorders (2) · Overnutrition (2) · Overweight (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Behavioral Symptoms (1) · Bone Diseases (1) · Bone Diseases, Metabolic (1)
Metformin (4) · empagliflozin (3) · alogliptin (2) · dapagliflozin (2) · Atorvastatin (1) · Insulin Aspart (1) · LC15-0444 (1) · Magnetic Resonance Spectroscopy (1) · Sodium-Glucose Transporter 2 Inhibitors (1) · Standard of Care (1) · Tai Ji (1) · Valsartan (1) · chiglitazar (1) · dulaglutide (1) · glucagon-like peptide 1 (7-36) (1)
Celltrion (2) · Guangdong Raynovent Biotech Co., Ltd (2) · Hangzhou Sciwind Biosciences Co., Ltd. (2) · The First Affiliated Hospital of Xiamen University (2) · Beijing Hospital (1) · Chengdu University of Traditional Chinese Medicine (1) · Chinese PLA General Hospital (1) · Chipscreen Biosciences, Ltd. (1) · Embecta Corp. (1) · Fujian Shengdi Pharmaceutical Co., Ltd. (1) · Hanmi Pharmaceutical Company Limited (1) · Huazhong University of Science and Technology (1) · Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Kunming Medical University (1)
China (19) · United States (4) · South Korea (2) · Australia (1) · Hungary (1) · Israel (1) · Jordan (1) · United Kingdom (1)
Anna Kahkoska, MD, PhD (1) · Bo Liu, pharmacist (1) · Congrong Wang, pharmacist (1) · Dalong Zhu (1) · Dandan Wu, pharmacist (1) · Deping Ho, pharmacist (1) · Donglou Liang, pharmacist (1) · Fang Liu, pharmacist (1) · Fujian Xu, pharmacist (1) · Guichun Wang, pharmacist (1) · Guifeng Tan, doctor (1) · Hongrong Xu (1) · Jiandong Jiang (1) · Jianfang Liu, pharmacist (1)
PMID 29397376, PMID 37780620, PMID 40854315, PMID 41501026, PMID 42148367